Literature DB >> 8118463

DNA mutational analysis of type 1 and type 3 Gaucher patients: how well do mutations predict phenotype?

E Sidransky1, A Bottler, B Stubblefield, E I Ginns.   

Abstract

The wide spectrum of clinical manifestations resulting from glucocerebrosidase deficiency complicates genetic counseling for Gaucher disease. The identification of mutations in the glucocerebrosidase gene has enabled studies of genotype-phenotype correlation. However, a genotypic analysis of 60 type 1 and type 3 Gaucher patients reveals that the 5 most common Gaucher mutations, N370S, L444P, R463C, 84insG, and IVS2 + 1 G-->A, can be found both in patients with and without neurologic manifestations. Moreover, although some generalizations can be made about mutations that are more frequently encountered in particular patient populations, Gaucher patients sharing identical genotypes can exhibit considerable clinical heterogeneity. Thus in considering rationale for population screening one cannot rely solely on PCR determined DNA mutation analysis to reliably predict prognosis in Gaucher disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8118463     DOI: 10.1002/humu.1380030105

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  12 in total

1.  Mutation analysis in 46 British and Irish patients with Gaucher's disease.

Authors:  C E Hatton; A Cooper; C Whitehouse; J E Wraith
Journal:  Arch Dis Child       Date:  1997-07       Impact factor: 3.791

2.  Decreased glucocerebrosidase activity in Gaucher disease parallels quantitative enzyme loss due to abnormal interaction with TCP1 and c-Cbl.

Authors:  Jie Lu; Jeffrey Chiang; Rajiv R Iyer; Eli Thompson; Christine R Kaneski; David S Xu; Chunzhang Yang; Masako Chen; Richard J Hodes; Russell R Lonser; Roscoe O Brady; Zhengping Zhuang
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-22       Impact factor: 11.205

3.  Type 2 Gaucher disease: the collodion baby phenotype revisited.

Authors:  D L Stone; W F Carey; J Christodoulou; D Sillence; P Nelson; M Callahan; N Tayebi; E Sidransky
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2000-03       Impact factor: 5.747

Review 4.  Alglucerase. A pharmacoeconomic appraisal of its use in the treatment of Gaucher's disease.

Authors:  R Whittington; K L Goa
Journal:  Pharmacoeconomics       Date:  1995-01       Impact factor: 4.981

5.  Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease.

Authors:  V Koprivica; D L Stone; J K Park; M Callahan; A Frisch; I J Cohen; N Tayebi; E Sidransky
Journal:  Am J Hum Genet       Date:  2000-05-04       Impact factor: 11.025

6.  Identification of three additional genes contiguous to the glucocerebrosidase locus on chromosome 1q21: implications for Gaucher disease.

Authors:  S L Winfield; N Tayebi; B M Martin; E I Ginns; E Sidransky
Journal:  Genome Res       Date:  1997-10       Impact factor: 9.043

7.  Phenotypic and genotypic heterogeneity in gaucher disease: Implications for genetic counseling.

Authors:  E Sidransky; E I Ginns
Journal:  J Genet Couns       Date:  1994-03       Impact factor: 2.537

Review 8.  Pediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statements.

Authors:  Gregory A Grabowski; Generoso Andria; Antonio Baldellou; Pauline E Campbell; Joel Charrow; Ian J Cohen; Chris M Harris; Paige Kaplan; Eugen Mengel; Miguel Pocovi; Ashok Vellodi
Journal:  Eur J Pediatr       Date:  2003-12-16       Impact factor: 3.183

9.  Evaluation of disease burden and response to treatment in adults with type 1 Gaucher disease using a validated disease severity scoring system (DS3).

Authors:  Neal J Weinreb; David N Finegold; Eleanor Feingold; Zhen Zeng; Barry E Rosenbloom; Suma P Shankar; Dominick Amato
Journal:  Orphanet J Rare Dis       Date:  2015-05-22       Impact factor: 4.123

10.  Variation in cognitive function over time in Gaucher disease type 3.

Authors:  Alta M Steward; Edythe Wiggs; Taylor Lindstrom; Somto Ukwuani; Emory Ryan; Nahid Tayebi; Tamanna Roshan Lal; Grisel Lopez; Raphael Schiffmann; Ellen Sidransky
Journal:  Neurology       Date:  2019-11-12       Impact factor: 11.800

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.